L
LifeCell International
Private stem cell bank that brings the concept of umbilical cord stem cell banking to india
About LifeCell International
LifeCell, established in 2004, is India's first and largest stem cell bank, trusted by over 350,000 parents who have banked their children's umbilical cord stem cells with the company. LifeCell operates in the healthcare sector, focusing on preventive care diagnostics and stem cell banking. The company serves a diverse clientele, primarily parents looking to secure their children's future health through stem cell preservation. LifeCell's business model revolves around offering stem cell banking services and preventive diagnostic tests, generating revenue through service fees and long-term storage plans. The company boasts state-of-the-art laboratories in Chennai and Gurgaon and a network of over 200 service centres across India. LifeCell aims to maximize the possibilities of good health for future generations by providing high-quality diagnostic and preventive care services. The company also partners with global leaders in stem cell technology to bring advanced cellular therapies to India. Keywords: stem cell banking, preventive diagnostics, healthcare, umbilical cord, state-of-the-art labs, Chennai, Gurgaon, Cryo Cell International, cellular therapies, India.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2004
- Headquarters
- Chennai, India
- Employees
- 2,662
- Open positions
- 7
- Dealroom signal
- 41.1/100
- Industry
- Health, Fintech
- Sub-industry
- BioTechnology, Banking
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech
- Investment activity
- 1 company, latest Jul 2022
- Capital deployed
- —
- Preferred round
- MERGER
Latest news
Press, funding announcements and product moves mentioning LifeCell International.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Jul 2022 | $0 | — | Mfine | ↗ |
| LATE VC✓Equity / VC | Sep 2021 | $35M | $138M | OrbiMed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for LifeCell International is 170K monthly website visits, down 10.5% over the last three months. LifeCell International's team grew 4.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Brand Capital
Helion Venture Partners
Series B and later1 investor entered at this stage
Other known investors2 additional known investors
Mfine- LILifeWell
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LifeCell International on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LifeCell International’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.